Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical-stage medical device innovator advancing the Hemopurifier® - a therapeutic filtration device targeting cancer-enabling exosomes and life-threatening viruses. This page provides investors and medical professionals with essential updates on clinical developments, regulatory progress, and strategic initiatives.
Key resources include press releases detailing trial protocols, ethics committee approvals, and operational milestones. Users will find verified information on oncology applications for treatment-resistant cancers and infectious disease programs, all presented in compliance with financial disclosure standards.
Content highlights encompass FDA communications, trial enrollment updates, and peer-reviewed research collaborations. The curated news collection serves as a reliable reference for tracking the Hemopurifier®'s progress through clinical validation stages and potential therapeutic applications.
Bookmark this page for direct access to Aethlon Medical's official announcements, including breakthrough device designations and international trial expansions. Check regularly for updates on this pioneering approach to blood filtration technology and its implications for cancer immunotherapy advancement.
Aethlon Medical (Nasdaq: AEMD), a medical therapeutic company developing products for cancer and infectious diseases treatment, announced it will release its fiscal second quarter financial results for the period ended September 30, 2024, on November 13, 2024 at 4:15 p.m. ET. The company will host a conference call at 4:30 p.m. ET the same day, featuring management's remarks and a Q&A session. Participants can register online or dial in directly, with replay available until December 13, 2024.
Aethlon Medical (Nasdaq: AEMD), a company developing products for cancer and infectious disease treatment, announced its participation in the 2024 Maxim Healthcare Virtual Summit. James Frakes, CEO and CFO, will engage in a fireside chat on October 15, 2024, at 4:30 pm ET.
The event, hosted by Anthony Vendetti, executive managing director and head of research at Maxim Group, offers an opportunity for investors to gain insights into Aethlon Medical's developments and strategies. Interested parties can access the company presentation by registering for the conference through the provided link.
Investorideas.com releases the second part of a series on immunotherapy for cancer treatment, featuring Aethlon Medical, Inc. (NASDAQ: AEMD). Key points include:
1. Immunotherapy shows promise in improving long-term survival for advanced melanoma patients.
2. Aethlon's Hemopurifier® aims to enhance anti-PD-1 therapy responses by removing tumor-produced extracellular vesicles.
3. Aethlon received ethics approval for a clinical trial in India, following approvals in Australia.
4. The trial will evaluate Hemopurifier® in solid tumor patients with stable or progressive disease during anti-PD-1 monotherapy.
5. Other companies like Immuneering and Iovance Biotherapeutics are also advancing immunotherapy treatments with promising results.
Aethlon Medical (Nasdaq: AEMD) has received full ethics approval from the Medanta Institutional Ethics Committee (MIEC) for its Hemopurifier® cancer trial in India. The trial, focusing on safety, feasibility, and dose-finding, will involve cancer patients with solid tumors not responding to anti-PD-1 antibodies like Keytruda® or Opdivo®. The study, to be conducted at Medanta Medicity Hospital, aims to evaluate the Hemopurifier as a treatment option for multiple tumor types.
The Hemopurifier is designed to remove tumor-produced extracellular vesicles (EVs) from the bloodstream, potentially improving response rates to anti-PD-1 therapies. The trial will involve 9-18 patients and monitor safety, adverse events, and changes in EV concentrations. Results are expected to inform future oncology efficacy trials and contribute to a subsequent Premarket Approval study.
Aethlon Medical (Nasdaq: AEMD), a company developing products for cancer and infectious diseases, has announced its participation in two virtual investor conferences in September 2024. The events are:
1. Life Sciences Investor Forum (Sept 19-20): James Frakes (Interim CEO/CFO) and Dr. Steven LaRosa (CMO) will present on Sept 19 at 1:30 pm ET. One-on-one meetings available.
2. Virtual Emerging Growth Conference (Sept 25): Presentation at 12:35 pm ET, followed by Q&A.
Both events offer live interaction, pre-registration, and archived webcasts. These conferences provide opportunities for investors to learn about Aethlon Medical's developments and engage with management directly.
The solid tumors market is expected to reach $375.4 Billion by 2034, with a CAGR of 7.45% from 2024-2034. Aethlon Medical (NASDAQ: AEMD) has activated a clinical trial site at Royal Adelaide Hospital for its Hemopurifier device in patients with solid tumors resistant to anti-PD-1 therapies. The trial aims to assess safety, feasibility, and dosing, with potential to improve response rates to immunotherapies by removing tumor-produced extracellular vesicles.
Other developments in the solid tumor space include Immuneering's positive initial data for IMM-1-104 in pancreatic cancer, and FDA approvals for new immunotherapy combinations from AstraZeneca, Merck, and GlaxoSmithKline for endometrial cancer. Roche's trastuzumab deruxtecan received accelerated approval for HER2-positive solid tumors across multiple cancer types.
Aethlon Medical (Nasdaq: AEMD) has announced the activation of the Cancer Clinical Trial Unit at Royal Adelaide Hospital to begin screening and enrolling patients for its Hemopurifier® clinical trial. The trial, focusing on patients with solid tumors not responding to anti-PD-1 antibodies, aims to assess safety, feasibility, and dosing of the Hemopurifier®.
Key points:
- Trial activation date: September 10, 2024
- Led by Prof. Michael Brown at Royal Adelaide Hospital, Australia
- Approximately 18 patients expected to participate
- Primary endpoint: Incidence of adverse events and safety lab changes
- Hemopurifier® designed to remove tumor-produced extracellular vesicles (EVs)
- Potential to improve response rates to anti-PD-1 therapies
Aethlon Medical (Nasdaq: AEMD) has published a preclinical study demonstrating the ability of its Hemopurifier® to remove extracellular vesicles (EVs) and microRNAs from renal perfusates following Controlled Oxygenated Rewarming of discarded donor kidneys. The study, published in bioRxiv on August 24, 2024, supports further research into using the Hemopurifier® as part of a machine perfusion circuit to assess its impact on retrieved kidney function.
The proof-of-concept study used four perfusates from discarded donor kidneys, confirming the removal of both small and larger size EVs and a significant reduction in microRNAs. This research could potentially address complications associated with extended criteria donor kidneys, which often result in poor graft function and acute rejection in recipients.
Aethlon Medical (AEMD) reported financial results for Q1 FY2025 ended June 30, 2024. Key highlights:
1. Received ethics approvals for Hemopurifier® trial in Australia for solid tumor patients not responding to anti-PD-1 antibodies.
2. Expects to open patient enrollment in October 2024.
3. Achieved 24% reduction in Q1 operating expenses vs. Q1 FY2024.
4. Cash balance of $9.1 million as of June 30, 2024.
5. Net loss decreased to $2.6 million in Q1 FY2025 from $3.3 million in Q1 FY2024.
6. Exploring Hemopurifier use for viral infections.
7. COVID-19 trial in India remains open.
Aethlon Medical, Inc. (NASDAQ: AEMD) has received ethics approval for a clinical trial of its Hemopurifier® device in patients with solid tumors. The trial, to be conducted at Pindara Private Hospital in Australia, will evaluate the safety and feasibility of the Hemopurifier® in patients with stable or progressive disease during anti-PD-1 monotherapy treatment.
The Hemopurifier® is designed to remove harmful exosomes from biological fluids, which may improve therapeutic response rates to anti-PD-1 antibodies. The device has shown promise in preclinical studies for reducing exosomes in cancer patient plasma samples.
This development comes as the solid tumor therapeutics market is projected to reach $885.44 Billion by 2033, with smaller companies making significant advancements in treatments alongside big pharma.
